The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
type 2 diabetics,
age between 18 and 80 years,
RAS blockade at maximal tolerated dosage for 1 month,
eGFR (CKD-EPI) between 10 and 20 ml/min/1.73m2,
any medical condition that, in the opinion of the investigator makes the participant not suitable for inclusion,
history of ketoacidosis in the past while on empagliflozin or any other SGLT2i class drugs,
participation in another clinical study with an investigational medicinal product (IMP) administered during the month before screening,
known hypersensitivity or intolerance to empagliflozin or any of the excipients of the product,
Centre Hospitalier Universitaire de Nice
Lead sponsor
Boehringer Ingelheim
Collaborator